Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020

The management of KPC-producing K. pneumoniae (KPC-Kp) in bloodstream infections (BSIs) represent a serious clinical challenge. In this study, the aim is to assess the incidence of resistance to novel β-lactams-β-lactamase inhibitor combinations (βL-βLICs), such as ceftazidime-avibactam (CAZ-AVI), m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bovo, Federica, Lombardo, Donatella, Lazzarotto, Tiziana, Ambretti, Simone, Gaibani, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686929/
https://www.ncbi.nlm.nih.gov/pubmed/36421265
http://dx.doi.org/10.3390/antibiotics11111621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686929/
https://www.ncbi.nlm.nih.gov/pubmed/36421265
http://dx.doi.org/10.3390/antibiotics11111621

Ejemplares similares